CD40L is a central immune activation signal involved in T-cell, B-cell, platelet, and antigen-presenting cell biology. SP001 combines several important attributes in one asset: a clinically relevant target, third-generation Fc-silent antibody engineering, and compelling potency signals. By targeting CD40L, SP001 is designed to intervene earlier in immune signaling than approaches focused primarily on downstream inflammatory mediators or single immune-cell populations.

SP001 is designed as an Fc-silent IgG1 monoclonal antibody to address Fc-mediated platelet activation concerns associated with first-generation molecules, while retaining important antibody properties, including long half-life. 

SP001 has demonstrated strong potency signals, including potent B-cell blockade and supportive anti-KLH immune response data. Its potential best-in-class profile is based on the combination of potency, Fc-silent engineering, and early clinical experience.

Spero is advancing SP001 in IgG4-RD, a serious relapsing fibroinflammatory condition characterized by chronic tissue inflammation, tissue fibrosis, and relapsing disease activity. Patients often face prolonged glucocorticoids exposure, relapse during or after steroid tapering, and repeated B-cell-directed therapies that can add to cumulative immune suppression and infection risk. CD40L signaling sits at the intersection of T-cell help, B-cell activation, plasmablast expansion, and fibroinflammatory disease biology. By interrupting this pathway, SP001 is designed to target a central driver of pathogenic immune collaboration rather than depleting B cells after disease-driving immune activation has already occurred. This mechanism gives SP001 the potential to deliver durable disease control, reduce dependence on chronic steroids, and provide a differentiated alternative to repeated B-cell depletion-based treatment.

Spero is also evaluating SP001 in additional indications, including Sjögren’s syndrome, a chronic, systemic autoimmune disorder. Spero’s partner, Innovent, is planning to initiate a Phase 2 study in Sjögren’s syndrome patients in China by early 2027.